Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Advanced Unresectable or Metastatic Solid Malignancy × tucatinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 7 Stomach Neoplasms 1 Ovarian Neoplasms 1 Neoplasms 1 HER2-positive Breast Cancer 1 Colorectal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Brain Neoplasms 1 Advanced Unresectable or Metastatic Solid Malignancy 1 Adenocarcinoma Of Esophagus 1

Interventions

tucatinib 1 pralsetinib 1 pertuzumab 1 ipatasertib 1 inavolisib 1 entrectinib 1 atezolizumab 1 alectinib 1 Trastuzumab 1 Tiragolumab 1 Paclitaxel 1 Ado-Trastuzumab Emtansine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04632992 2025-01-08

MyTACTIC

Genentech, Inc.

Phase 2 Completed

252 enrolled 27 charts

Advanced Unresectable or Metastatic Solid Malignancy

Data powered by HemOnc (CC BY 4.0) Colophon ⚡